Key Concepts of Clinical Trials: A Narrative Review

References

• . American Recovery and Reinvestment Act of 2009. H.R. 1st ed; 2009
   Google Scholar
• . Trials of War Criminals Before the Nuremberg Military Tribunals Under Control Council Law. No. 10, Vol. 2. Washington, DC: US Government Printing Office; 1949:181–182
   Google Scholar
• . World Medical Organization. Declaration of Helsinki. December 7, 1996. BMJ. 1996:1448–1449
   Google Scholar
• . Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987; 317(3):141–145
   PubMed Web of Science ®Google Scholar
• . Department of Health and Welfare. The Belmont report: ethical principles and guidelines for the protection of human subjects of research. Washington, DC: OPRR Reports; 1979
   Google Scholar
• . Brandt AM. Racism and research: The case of the Tuskegee Syphilis Study. Hastings Cent Rep. 1978; 8(6):21–29
   PubMed Web of Science ®Google Scholar
• . Code of Federal Regulations—The Common Rule: Protection of Human Subjects. In: Services DoHaH, ed. Vol 45. 2009
   Google Scholar
• . Lansimies-Antikainen H, Laitinen T, Rauramaa R, Pietilä AM. Evaluation of informed consent in health research: A questionnaire survey. Scand J Caring Sci. 2010; 24(1):56–64
   PubMed Web of Science ®Google Scholar
• . Ridpath JR, Wiese CJ, Greene SM. Looking at research consent forms through a participant-centered lens: The PRISM readability toolkit. Am J Health Promot. 2009; 23(6):371–375
   PubMed Web of Science ®Google Scholar
• . Gravetter FJ, Forzano LAB. Research Methods for the Behavioral Sciences. 3rd ed. Belmont, CA: Wadsworth Cengage Learning; 2009
   Google Scholar
• . Mapstone J, Elbourne D, Roberts I. Strategies to improve recruitment to research studies. Cochrane Database Syst Rev. 2007;(2):MR000013
   Google Scholar
• . Treweek S, Mitchell E, Pitkethly M, . Strategies to improve recruitment to randomised controlled trials. Cochrane Database Syst Rev. 2010;(1):MR000013
   Google Scholar
• . Dickert N, Grady C. What's the price of a research subject? Approaches to payment for research participation. N Engl J Med. 1999; 341(3):198–203
   PubMed Web of Science ®Google Scholar
• . Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med. 1989; 8(4):431–440
   PubMed Web of Science ®Google Scholar
• . Chobanian AV, Bakris GL, Black HR, ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med. 1996; 125(7):605–613
   PubMed Web of Science ®Google Scholar
• . Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA. 1999; 282(8):790–795
   PubMed Web of Science ®Google Scholar
• . Echt DS, Liebson PR, Mitchell LB, . Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324(12):781–788
   PubMed Web of Science ®Google Scholar
• . A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med. 1991; 324(8): 509–516
   PubMedGoogle Scholar
• . Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points—the challenge of statistical validation. Nat Rev Clin Oncol. 2010; 7(6):309–317
   PubMed Web of Science ®Google Scholar
• . International Conference on Harmonisation. Good clinical practice guidelines for essential documents for the conduct of a clinical trial. Geneva, Switzerland: ICH Secretariat c/o IFPMA. 1994
   Google Scholar
• . Roberts TG Jr, Goulart BH, Squitieri L, . Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004; 292(17):2130–2140
   PubMed Web of Science ®Google Scholar
• . Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent in cancer clinical trials: A cross-sectional survey. Lancet. 2001; 358(9295):1772–1777
   PubMed Web of Science ®Google Scholar
• . Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: A statistical reminder. BMJ. 1995; 311(7005):619–620
   PubMed Web of Science ®Google Scholar
• . Cahana A, Romagnioli S. Not all placebos are the same: A debate on the ethics of placebo use in clinical trials versus clinical practice. J Anesth. 2007; 21(1):102–105
   PubMed Web of Science ®Google Scholar
• . Foddy B. A duty to deceive: Placebos in clinical practice. Am J Bioeth. 2009; 9(12):4–12
   PubMed Web of Science ®Google Scholar
• . Wilcox CM. Exploring the use of the sham design for interventional trials: Implications for endoscopic research. Gastrointest Endosc. 2008; 67(1):123–127
   PubMed Web of Science ®Google Scholar
• . Levine RJ. The need to revise the Declaration of Helsinki. N Engl J Med. 1999; 341(7):531–534
   PubMed Web of Science ®Google Scholar
• . Vastag B. Helsinki discord? A controversial declaration. JAMA. 2000; 284(23):2983–2985
   PubMed Web of Science ®Google Scholar
• . Walker E, Nowacki AS. Understanding equivalence and noninferiority testing. J Gen Intern Med. 2011; 26(2):192–196
   PubMed Web of Science ®Google Scholar
• . Fleming TR. Current issues in non-inferiority trials. Stat Med. 2008; 27(3):317–332
   PubMed Web of Science ®Google Scholar
• . Doll R. Sir Austin Bradford Hill and the progress of medical science. BMJ. 1992; 305(6868):1521–1526
   PubMedGoogle Scholar
• . Hill AB. Medical ethics and controlled trials. Br Med J. 1963; 1(5337): 1043–1049
   PubMed Web of Science ®Google Scholar
• . Scott NW, McPherson GC, Ramsay CR, Campbell MK. The method of minimization for allocation to clinical trials: A review. Control Clin Trials. 2002; 23(6):662–674
   PubMedGoogle Scholar
• . Tsiatis A. Methodological issues in AIDS clinical trials. Intent-to-treat analysis. J Acquir Immune Defic Syndr. 1990; 3( suppl 2):S120–S123
   PubMed Web of Science ®Google Scholar
• . Moher D, Schulz KF, Altman D; CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001; 285(15):1987–1991
   PubMed Web of Science ®Google Scholar
• . Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ. 2010; 340:c332
   PubMed Web of Science ®Google Scholar
• . Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance—lack of vigilance, lack of trust. JAMA. 2004; 292(21):2647–2650
   PubMed Web of Science ®Google Scholar
• . Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective. Clin Pharmacol Ther. 1995; 58(1):108–117
   PubMed Web of Science ®Google Scholar
• . Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002; 287(17):2215–2220
   PubMed Web of Science ®Google Scholar
• . Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: A counterpoint. JAMA. 2004; 292(21): 2643–2646
   PubMed Web of Science ®Google Scholar
• . AERS patient outcomes by year. In: Administration USFaD, ed. 2010. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070461.htm. Updated March 31, 2011. Accessed June 29, 2011
   Google Scholar
• . James WP, Caterson ID, Coutinho W, . Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010; 363(10):905–917
   PubMed Web of Science ®Google Scholar
• . Maro JC, Platt R, Holmes JH, . Design of a national distributed health data network. Ann Intern Med. 2009; 151(5):341–344
   PubMed Web of Science ®Google Scholar
• . Berlin JA, Colditz GA. The role of meta-analysis in the regulatory process for foods, drugs, and devices. JAMA. 1999; 281(9):830–834
   PubMed Web of Science ®Google Scholar
• . Hennekens CH, Demets D. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. JAMA. 2009; 302(21):2361–2362
   PubMed Web of Science ®Google Scholar
• . Mello MM, Studdert DM, Brennan TA. The rise of litigation in human subjects research. Ann Intern Med. 2003; 139(1):40–45
   PubMed Web of Science ®Google Scholar
• . Steinbrook R. Protecting research subjects—the crisis at Johns Hopkins. N Engl J Med. 2002; 346(9):716–720
   PubMed Web of Science ®Google Scholar
• . Ellenberg S, Fleming TR, DeMets DL. Data Monitoring Committees in Clinical Trials: A Practical Perspective: West Sussex, England: John Wiley & Sons; 2002
   Google Scholar
• . Guidance for Industry. E6. Good clinical practice—consolidated guidance. Bethesda, MD: US Department of Health and Human Services; 1996
   Google Scholar
• . Issa AM, Phillips KA, Van Bebber S, . Drug withdrawals in the United States: A systematic review of the evidence and analysis of trends. Curr Drug Saf. 2007; 2(3):177–185
   PubMedGoogle Scholar